Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4609179 | 1.00 | MAPK14 (0.62) | MAPK14HPGDHCAR3ALDH1A1HTT | |
| SCHEMBL4625103 | 0.92 | MAPK14 (0.65) | MAPK14HPGDHCAR3ALDH1A1HTT | |
| SCHEMBL4608596 | 0.92 | MAPK14 (0.65) | MAPK14HPGDHCAR3ALDH1A1HTT | |
| SCHEMBL4609540 | 0.91 | MAPK14 (0.71) | MAPK14 | |
| SCHEMBL4609310 | 0.91 | MAPK14 (0.59) | MAPK14HPGDHCAR3ALDH1A1HTT | |
| SCHEMBL4609305 | 0.91 | MAPK14 (0.59) | MAPK14HPGDHCAR3ALDH1A1HTT | |
| SCHEMBL4609534 | 0.91 | MAPK14 (0.71) | MAPK14 | |
| SCHEMBL4608523 | 0.90 | MAPK14 (0.58) | MAPK14HCAR3ALDH1A1 | |
| SCHEMBL4608522 | 0.90 | MAPK14 (0.58) | MAPK14HCAR3ALDH1A1 | |
| SCHEMBL4608723 | 0.89 | MAPK14 (0.64) | MAPK14HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449474-B2 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-11-11 | — | — | US | claimed |
| EP-1747204-B1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | PROCTER & GAMBLE (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1747204-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | The Procter and Gamble Company (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005105758-A1 | TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239811-A1 | Tri-substituted ureas as cytokine inhibitors | IL1B, IL1A, IL6 | MAPK14 2674/4885HPGD 612/4885HCAR3 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.